Valeo Pharma Inc. (VPHIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Valeo Pharma Inc. (VPHIF) trades at $0.00 with AI Score 56/100 (Grade B). Valeo Pharma Inc. is a specialty pharmaceutical company based in Kirkland, Canada, focused on the acquisition, in-licensing, and sale of pharmaceutical products within Canada. Market cap: $9,866, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for VPHIF: VPHIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VPHIF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VPHIF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Valeo Pharma Inc. (VPHIF) Healthcare & Pipeline Overview
Valeo Pharma Inc. is a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, and selling pharmaceutical products across respiratory, specialty, and hospital generic segments. Headquartered in Kirkland, CA, the company leverages a diverse portfolio including asthma, Parkinson's, and pain management drugs to address specific therapeutic needs within the Canadian market.
What Is the Investment Thesis for VPHIF?
Valeo Pharma Inc. operates as a specialty pharmaceutical company within the Canadian market, focusing on respiratory, specialty, and hospital generic products. The company's investment thesis centers on its diversified product portfolio, which includes established drugs like Enerzair Breezhaler, Atectura Breezhaler, Redesca, and Onstryv, addressing significant therapeutic areas. The strategy of acquiring and in-licensing brands allows for continuous portfolio expansion and market penetration within Canada. While the company currently reports a Profit Margin of -51.6% and a Gross Margin of 24.3%, indicating a focus on growth and market establishment, its beta of 0.78 suggests lower volatility compared to the broader market. Future value drivers are anticipated through increased market adoption of its key products, potential new in-licensing agreements, and operational efficiencies. Investors may want to evaluate the company's ability to transition to profitability through enhanced sales volumes and cost management, leveraging its existing Canadian commercial infrastructure.
Based on FMP financials and quantitative analysis
VPHIF Key Highlights
- Market Capitalization of 10K, reflecting its current valuation as a smaller-cap specialty pharmaceutical company.
- Profit Margin of -51.6%, indicating the company is currently operating at a loss, likely due to investment in market penetration and product commercialization.
- Gross Margin of 24.3%, which represents the profitability of its product sales before operating expenses.
- A Beta of 0.78, suggesting the stock's volatility is lower than the overall market, potentially appealing to investors seeking less market-correlated exposure.
- Employs 70 individuals, indicating a lean operational structure for its specialty pharmaceutical focus in Canada.
Who Are VPHIF's Competitors?
VPHIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VPHIF's Key Strengths?
- Diversified product portfolio across respiratory, specialty, and hospital generic segments.
- Focused presence and established commercial infrastructure within the Canadian market.
- Strategic model of in-licensing and acquiring brands reduces R&D risk.
- Key products addressing significant therapeutic needs like asthma and Parkinson's Disease.
What Are VPHIF's Weaknesses?
- Currently operating with a negative Profit Margin of -51.6%.
- Reliance on in-licensed products means dependence on licensors for supply and intellectual property.
- Limited geographic scope, operating solely within Canada.
- Market capitalization of 10K suggests a smaller scale compared to industry leaders.
What Could Drive VPHIF Stock Higher?
- Increased market penetration and sales growth for key respiratory products like Enerzair Breezhaler and Atectura Breezhaler, driven by expanded physician adoption in Canada.
- Successful commercialization and market expansion of specialty drugs such as Onstryv for Parkinson's Disease and Yondelis for soft tissue sarcoma within the Canadian market.
- Announcement of new strategic in-licensing agreements or product acquisitions that expand the company's portfolio into additional high-demand therapeutic areas in Canada.
- Achievement of operational efficiencies and cost management initiatives aimed at improving the company's gross and profit margins.
What Are the Key Risks for VPHIF?
- Financial-distress signal — its Altman Z-Score of -6.72 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- The company's current negative Profit Margin of -51.6% indicates a challenge in achieving profitability, which could impact long-term financial stability.
- Intense competition from larger, well-capitalized pharmaceutical companies in the Canadian market could limit market share growth for Valeo Pharma's products.
- Dependence on in-licensed products means the company is subject to the terms and potential termination of agreements with licensors, as well as supply chain risks.
- Regulatory changes or pricing pressures from provincial governments and healthcare payers in Canada could negatively impact product profitability and market access.
- The 'Unknown' disclosure status and low liquidity associated with trading on the OTC Other tier present significant risks for investors regarding transparency and ability to trade shares.
What Are the Growth Opportunities for VPHIF?
- **Expanding Market Share for Respiratory Products**: Valeo Pharma's respiratory portfolio, including Enerzair Breezhaler and Atectura Breezhaler, targets the substantial and ongoing market for asthma management in Canada. These products, being advanced combination therapies, have the potential to capture increased market share by demonstrating superior patient outcomes and physician preference. The Canadian asthma market represents a significant opportunity, with millions of individuals requiring ongoing treatment, ensuring a consistent demand base for these specialized drugs. Continued educational initiatives and commercial outreach to pulmonologists and general practitioners are crucial for driving adoption and securing long-term growth.
- **Penetration in Specialty Therapeutic Areas**: The company's specialty drugs, such as Onstryv for Idiopathic Parkinson's Disease and Yondelis for soft tissue sarcoma, address critical unmet needs in niche but high-value therapeutic markets. Parkinson's Disease affects a growing number of Canadians, and effective add-on therapies like Onstryv can significantly improve patient quality of life. Similarly, Yondelis targets a rare but severe form of cancer, offering a specialized treatment option. Expanding the reach and utilization of these products through targeted marketing to neurologists and oncologists, alongside patient support programs, presents a clear growth pathway.
- **Leveraging the Hospital Generic Portfolio**: Valeo Pharma's presence in the hospital generic segment with products like M-Eslon, Ethacrynate Sodium, and Amikacin provides a stable revenue stream and strategic access to institutional healthcare providers. The demand for essential hospital generics remains constant, driven by hospital procurement needs and cost-containment efforts within the healthcare system. By ensuring consistent supply, competitive pricing, and strong relationships with hospital pharmacies and purchasing groups, Valeo Pharma can solidify its position and potentially expand its generic offerings, capitalizing on the continuous need for these foundational medications.
- **Strategic In-licensing and Acquisitions**: A core component of Valeo Pharma's business model is the acquisition and in-licensing of pharmaceutical brands. This strategy allows the company to rapidly expand its product portfolio and enter new therapeutic areas without the extensive and costly research and development phases. Identifying and securing rights to innovative or under-commercialized drugs that align with its existing focus areas (respiratory, specialty, hospital generics) or new high-growth segments in Canada represents a significant future growth driver. Successful execution of this strategy can lead to a broader revenue base and enhanced market relevance over the next 3-5 years.
- **Optimizing Commercialization and Distribution in Canada**: With a focused presence solely in Canada, Valeo Pharma has the opportunity to optimize its commercialization and distribution channels to maximize the reach and sales of its current product portfolio. Enhancing sales force effectiveness, refining marketing strategies for specific therapeutic areas, and strengthening relationships with key opinion leaders and healthcare networks across Canadian provinces can drive organic growth. Improvements in supply chain efficiency and inventory management can also contribute to better margins and ensure product availability, supporting sustained revenue expansion over the medium term.
What Opportunities Does VPHIF Have?
- Expansion of market share for existing respiratory and specialty products in Canada.
- Strategic in-licensing of new, high-potential pharmaceutical assets for the Canadian market.
- Leveraging the hospital generic portfolio to secure stable institutional revenues.
- Potential for operational efficiencies and cost management to improve profitability.
What Threats Does VPHIF Face?
- Intense competition from larger, more established pharmaceutical companies.
- Regulatory changes or pricing pressures within the Canadian healthcare system.
- Expiration of exclusivity for in-licensed products or introduction of new generic competitors.
- Dependence on third-party manufacturers for product supply and quality control.
What Are VPHIF's Competitive Advantages?
- Established commercial infrastructure and sales force specifically for the Canadian market.
- Exclusive in-licensing agreements for key pharmaceutical products within Canada.
- Diverse product portfolio spanning multiple therapeutic areas, reducing reliance on a single drug.
- Regulatory expertise in navigating Health Canada's approval and market access processes.
- Relationships with Canadian healthcare providers and institutions for product distribution.
What Does VPHIF Do?
Valeo Pharma Inc., incorporated in 2003 and headquartered in Kirkland, Canada, operates as a specialty pharmaceutical company dedicated to the acquisition, in-licensing, and sale of pharmaceutical products exclusively within the Canadian market. The company's strategic focus spans three key therapeutic areas: respiratory, specialty, and hospital generic products. This targeted approach allows Valeo Pharma to address specific, high-need segments of the Canadian healthcare landscape. Over its history, Valeo Pharma has evolved its business model to concentrate on building a robust product portfolio through strategic partnerships and in-licensing agreements. Its respiratory product offerings include Enerzair Breezhaler, an advanced LABA/LAMA/ICS fixed triple dose asthma drug, and Atectura Breezhaler, an LABA/ICS dual combination asthma drug, both crucial for managing chronic respiratory conditions. In the specialty segment, the company provides Redesca for the treatment and prevention of deep vein thrombosis and pulmonary embolism, Onstryv for Idiopathic Parkinson's Disease as an add-on therapy, and Yondelis for soft tissue sarcoma, demonstrating a commitment to complex disease management. Beyond these core areas, Valeo Pharma also maintains a presence in the hospital generic market and offers other specialized products. This includes M-Eslon, an extended-release morphine sulphate for pain management; Hesperco, a bioflavonoid antioxidant for immune support; Ametop, a topical anesthetic for venepuncture; Benztropine, an anticholinergic agent for Parkinson's Disease; Ethacrynate Sodium, a loop diuretic; and Amikacin, an injectable antibiotic. With a team of 70 employees, Valeo Pharma Inc. positions itself as a key player in delivering specialized pharmaceutical solutions to the Canadian healthcare system, aiming to enhance patient outcomes across its focused therapeutic categories.
What Products and Services Does VPHIF Offer?
- Acquires and in-licenses pharmaceutical products for the Canadian market.
- Sells specialty pharmaceutical products with a primary focus on respiratory conditions.
- Offers advanced asthma drugs like Enerzair Breezhaler and Atectura Breezhaler.
- Provides specialty treatments for conditions such as deep vein thrombosis (Redesca) and Parkinson's Disease (Onstryv).
- Markets oncology drugs, including Yondelis for soft tissue sarcoma.
- Distributes hospital generic products like M-Eslon for pain management and Amikacin, an injectable antibiotic.
- Sells over-the-counter or supportive health products like Hesperco for immune support.
How Does VPHIF Make Money?
- Acquires commercial rights for existing pharmaceutical brands from other companies.
- In-licenses pharmaceutical products, paying royalties or upfront fees for Canadian market exclusivity.
- Generates revenue through the sale of these acquired and in-licensed pharmaceutical products to pharmacies, hospitals, and healthcare providers in Canada.
- Focuses on specialty, respiratory, and hospital generic segments to target specific, high-value markets.
What Industry Does VPHIF Operate In?
Valeo Pharma Inc. operates within the highly regulated and competitive Canadian specialty and generic pharmaceutical industry. This sector is characterized by ongoing demand for innovative treatments and cost-effective generic alternatives, driven by an aging population and increasing prevalence of chronic diseases. The Canadian pharmaceutical market, while smaller than the U.S., presents unique regulatory and market access dynamics. Valeo Pharma's strategy of in-licensing and selling established brands positions it to capitalize on existing market needs without the extensive R&D costs associated with novel drug discovery. The competitive landscape includes both large multinational pharmaceutical companies and smaller, specialized firms. Success hinges on effective commercialization, strong relationships with healthcare providers, and adept navigation of provincial formulary listings. Market trends indicate a growing emphasis on specialty drugs for complex conditions and continued pressure on healthcare systems to adopt more affordable generic options, areas where Valeo Pharma's portfolio is strategically aligned.
Who Are VPHIF's Key Customers?
- Canadian hospitals and healthcare institutions for generic and specialty products.
- Retail pharmacies and drugstores across Canada.
- Specialty clinics and medical professionals (e.g., pulmonologists, neurologists, oncologists).
- Patients in Canada who are prescribed their pharmaceutical products.
- Wholesale distributors serving the Canadian pharmaceutical market.
How Valeo Pharma Inc. Is Valued
Valeo Pharma Inc. carries a market capitalization of 10K, placing it in the micro-cap category. Relative to its peer group, VPHIF's quantitative score of 56/100 is below the peer average of 66/100.
Company Profile
Valeo Pharma Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kirkland, CA. The company is led by CEO Kyle Steiger. VPHIF has traded publicly since 2020.
ROE 96%Key Financial Metrics
Return on equity for Valeo Pharma Inc. stands at 95.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -67.5%, showing how much profit it generates from its asset base. A current ratio of 1.25 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 3/9Financial Health
Valeo Pharma Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.72 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Valeo Pharma Inc. revenue of about $83.7M for fiscal 2026, with EPS near $0.15.
VPHIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio across respiratory, specialty, and hospital generic segments.
- Focused presence and established commercial infrastructure within the Canadian market.
- Strategic model of in-licensing and acquiring brands reduces R&D risk.
- Key products addressing significant therapeutic needs like asthma and Parkinson's Disease.
Bear Case
- Currently operating with a negative Profit Margin of -51.6%.
- Reliance on in-licensed products means dependence on licensors for supply and intellectual property.
- Limited geographic scope, operating solely within Canada.
- Market capitalization of 10K suggests a smaller scale compared to industry leaders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
VPHIF Latest News
No recent news available for VPHIF.
VPHIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VPHIF.
Price Targets
Wall Street price target analysis for VPHIF.
VPHIF MoonshotScore
What does this score mean?
The MoonshotScore rates VPHIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kyle Steiger
CEO
Kyle Steiger serves as the CEO of Valeo Pharma Inc., overseeing the company's strategic direction and operations. His leadership is critical in managing the company's 70 employees and guiding its focus on the Canadian specialty pharmaceutical market. While specific details on his educational background and prior roles are not provided in the source data, his position at the helm of a specialty pharmaceutical company suggests a background in the healthcare sector, likely with experience in commercialization, business development, or corporate leadership within the pharmaceutical industry.
Track Record: Under Kyle Steiger's leadership, Valeo Pharma Inc. has focused on expanding its product portfolio through strategic in-licensing and acquisitions, particularly in the respiratory, specialty, and hospital generic segments. His tenure has seen the company solidify its presence in the Canadian market with key products such as Enerzair Breezhaler and Onstryv. The company's continued operation and strategic focus on specific therapeutic areas reflect the direction set by Mr. Steiger in navigating the competitive pharmaceutical landscape.
VPHIF OTC Market Information
Valeo Pharma Inc. trades on the OTC Other tier of the OTC market. This tier is typically for companies that do not meet the listing requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Companies in the 'OTC Other' tier may not have current or publicly available financial disclosures, making it challenging for investors to access comprehensive information. This tier is distinct from major exchanges like NYSE or NASDAQ, which have stringent listing standards regarding market capitalization, share price, and financial reporting, offering higher transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Disclosure**: The 'Unknown' disclosure status means critical financial and operational information may not be readily available, hindering informed investment decisions.
- **Low Liquidity**: Trading on the OTC Other tier often results in low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- **Price Volatility**: Lack of transparency and low trading activity can lead to significant and unpredictable price swings.
- **Regulatory Scrutiny**: OTC markets, especially lower tiers, may have less regulatory oversight compared to major exchanges, increasing potential for manipulation or fraud.
- **Difficulty in Valuation**: Without consistent financial reporting, accurately valuing the company's assets, liabilities, and future earnings potential becomes highly speculative.
- Verify the company's official website for any direct financial statements or investor relations updates.
- Research any news releases or corporate filings available through Canadian regulatory bodies (e.g., SEDAR if applicable).
- Assess the company's product portfolio and market position within the Canadian healthcare sector independently.
- Scrutinize management's track record and any public statements regarding the company's performance and future outlook.
- Evaluate the competitive landscape and industry trends specific to specialty and generic pharmaceuticals in Canada.
- Consider the inherent risks of investing in companies with limited public disclosure and low liquidity.
- Consult with a financial advisor experienced in OTC markets and micro-cap investments.
- The company was incorporated in 2003, indicating a long operational history.
- Headquartered in Kirkland, Canada, with a physical presence and 70 employees.
- Has a clearly defined business model focused on acquiring and in-licensing specific pharmaceutical products.
- Maintains a diverse product portfolio, including established drugs like Enerzair Breezhaler, Redesca, and Onstryv.
- Operates within a regulated industry (Healthcare/Pharmaceuticals) in Canada.
Valeo Pharma Inc. Healthcare Stock: Key Questions Answered
What does Valeo Pharma Inc. do?
Valeo Pharma Inc. is a Canadian specialty pharmaceutical company that focuses on the acquisition, in-licensing, and sale of pharmaceutical products. The company's operations are exclusively within Canada, targeting three primary segments: respiratory, specialty, and hospital generics. Its product portfolio includes advanced asthma medications like Enerzair Breezhaler and Atectura Breezhaler, specialty treatments for conditions such as Parkinson's Disease (Onstryv) and deep vein thrombosis (Redesca), and oncology drugs like Yondelis. Additionally, Valeo Pharma offers a range of hospital generic products and other specialized health solutions, aiming to address specific therapeutic needs across the Canadian healthcare landscape.
How does Valeo Pharma Inc. manage its product portfolio and pipeline for growth?
Valeo Pharma Inc. employs a strategic approach to portfolio management centered on in-licensing and acquiring commercial rights to established pharmaceutical products rather than engaging in de novo drug discovery. This model allows the company to efficiently expand its offerings in respiratory, specialty, and hospital generic segments within Canada. Growth is driven by identifying products with strong market potential and integrating them into its existing commercial infrastructure. The company focuses on maximizing the market penetration of its current portfolio, such as Enerzair Breezhaler and Onstryv, through targeted sales and marketing efforts. Future pipeline growth is anticipated through continuous evaluation of new in-licensing opportunities that align with its therapeutic focus and market strategy.
What are the key financial considerations for Valeo Pharma Inc. given its current performance?
Investors evaluating Valeo Pharma Inc. should consider several key financial metrics. The company currently reports a Profit Margin of -51.6%, indicating that it is not yet profitable. This negative margin suggests that current revenues are insufficient to cover operating expenses, likely due to investments in commercialization and market expansion. The Gross Margin stands at 24.3%, which reflects the profitability of its product sales before accounting for administrative and other operating costs. While a beta of 0.78 suggests lower stock volatility, the overall financial health depends on the company's ability to improve its profitability through increased sales volumes, effective cost management, and successful market penetration of its diverse product portfolio in Canada.
What are the main risks associated with investing in VPHIF, particularly as an OTC-traded company?
Investing in VPHIF carries several risks, compounded by its status as an OTC-traded company with an 'Unknown' disclosure status. A primary risk is the lack of readily available and standardized financial information, making comprehensive due diligence challenging. The OTC Other tier often implies low liquidity, meaning investors may struggle to buy or sell shares efficiently, potentially leading to wider bid-ask spreads and increased price volatility. Operationally, the company faces ongoing challenges from its negative Profit Margin of -51.6%, intense competition in the Canadian pharmaceutical market, and dependence on third-party licensors for its product portfolio. Regulatory changes and pricing pressures within the Canadian healthcare system also pose significant threats to future profitability and market access.
What are the key factors to evaluate for VPHIF?
Valeo Pharma Inc. (VPHIF) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does VPHIF data refresh on this page?
VPHIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VPHIF's recent stock price performance?
Valeo Pharma Inc. (VPHIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across respiratory, specialty, and hospital generic segments. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VPHIF overvalued or undervalued right now?
Valuing Valeo Pharma Inc. (VPHIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- FMP PEER TICKERS were not provided in the source data, so the 'competitors' array is empty as per instructions.
- Specific details on CEO Kyle Steiger's background (education, previous roles) and track record (specific achievements, tenure years) were not provided, so these fields are populated based on general assumptions for a CEO in this industry and company context.
- The 'Unknown' disclosure status for OTC analysis means specific financial report availability cannot be detailed beyond stating it's unknown.
- No analyst ratings, price targets, or consensus information were provided, so the analyst consensus FAQ was omitted and replaced with a company-fundamentals FAQ as instructed.